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Continuous positive airway pressure (CPAP) ventilation may be used as a potential bridge
to invasive mechanical ventilation (IMV), or as a ceiling-of-care for persistent hypoxaemia
despite standard oxygen therapy, according to UK guidelines. We examined the association
of mode of respiratory support and ceiling-of-care on mortality.
Methods
We conducted a retrospective cohort analysis of routinely collected de-identified data of
adults with nasal/throat SARs-CoV-2 swab-positive results, at the Calderdale and Hudders-
field NHS Foundation Trust between 10th March-19th April 2020 (outcomes determined on
22nd May).
Findings
Of 347 patients with SARs-CoV-2 swab-positive results, 294 (84.7%) patients admitted for
Covid-19 were included in the study. Sixty-nine patients were trialled on CPAP, mostly deliv-
ered by face mask, either as an early ceiling of care instituted within 24 hours of admission
(N = 19), or as a potential bridge to IMV (N = 44). Patients receiving a ceiling of care more
than 24 hours after admission (N = 6) were excluded from the analysis. Two hundred and
fifteen patients (73.1%) maximally received air/standard oxygen therapy, and 45 (15.3%)
patients maximally received CPAP. Thirty-four patients (11.6%) required IMV, of which 24
had received prior CPAP. There were 138 patients with an early ceiling-of-care plan (pre-
admission/within 24h). Overall, 103(35.0%) patients died and 191(65.0%) were alive at
study end. Among all patients trialled on CPAP either as a potential bridge to IMV (N = 44)
or as a ceiling-of-care (N = 19) mortality was 25% and 84%, respectively. Overall, there was
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strong evidence for higher mortality among patients who required CPAP or IMV, compared
to those who required only air/oxygen (aOR 5.24 95%CI: 1.38, 19.81 and aOR 46.47 95%
CI: 7.52, 287.08, respectively; p<0.001), and among patients with early ceiling-of-care com-
pared to those without a ceiling (aOR 41.81 95%CI: 8.28, 211.17; p<0.001). Among patients
without a ceiling of care (N = 137), 10 patients required prompt intubation following failed
oxygen therapy, but 44 patients received CPAP. CPAP failure, defined as death (N = 1) or
intubation (N = 24), occurred in 57% (N = 25) of patients. But in total, 75% (N = 33) of those
started on CPAP with no ceiling of care recovered to discharge—19 without the need for
IMV, and 14 following IMV.
Conclusion
Our data suggest that among patients with no ceiling-of-care, an initial trial of CPAP as a
potential bridge to IMV offers a favourable therapeutic alternative to early intubation. In con-
trast, among patients with a ceiling-of care, CPAP seems to offer little additional survival
benefit beyond oxygen therapy alone. Information on ceilings of respiratory support is vital
to interpreting mortality from Covid-19.
Strengths and limitations of this study
• Sample size relatively small.
• Study sample representative of hospitalised Covid-19 patients in UK.
• Previously unreported data on role of ceilings-of-care in hospitalised Covid-19 patients.
• Novel data on use of CPAP separated by indication.
Background
SARS-CoV-2 infection which causes Covid-19 was declared a global pandemic by the World
Health Organization (WHO) on March 11th 2020. An estimated seven million people have
been infected globally, with approximately 400, 000 recorded deaths as of 11th June 2020 [1].
In the absence of definitive treatment for SARS-CoV-2, oxygen and respiratory support is
the mainstay of management to prevent death. As such, information on the presence of ceil-
ings-of-care which limit escalation of respiratory support is vital to interpreting mortality
outcomes [2].
Disease severity from Covid-19 varies widely and invasive mechanical ventilation (IMV)
has been used in 8–29% of hospitalised patients [3,4]. In the UK, data suggest that mortality
in patients who require IMV is approximately 50% [5]. Current World Health Organization
(WHO) guidelines for the management of Covid-19 recommend that a trial of continuous
positive airway pressure (CPAP) ventilation may be considered in patients who remain hypox-
emic despite standard oxygen therapy (via nasal prongs or Venturi face mask), however this
was not initially the case earlier in the pandemic [6,7]. The use of CPAP in Covid-19 has been
questioned [8], but in contrast to many other healthcare settings, CPAP is used in the UK in
preference to High Flow Nasal Oxygen, largely due to concerns about oxygen supplies. In the
UK, CPAP for the management of hypoxemic patients who are admitted to hospital with
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Covid-19 is indicated as a potential bridge to IMV for patients with no ceilings to their poten-
tial care pathways, as a ceiling-of-care and to facilitate extubation [9]. This paper focuses on
the first two of these three indications.
A ceiling-of-care is considered in order to avoid unwanted interventions that carry a high
risk of failure and unnecessary suffering. All adults admitted to hospital are assessed for frailty
and other factors which may make IMV on the Intensive Care Unit (ICU) inappropriate as a
treatment modality [10]. When relevant, a treatment escalation and limitation plan is agreed
by consensus between clinician, patient and family. This usually involves a “Do not Attempt
Cardiopulmonary Resuscitation” order (DNACPR) which almost invariably excludes treat-
ment with IMV. In this case, a trial of CPAP may be considered for patients who require
greater respiratory support than standard oxygen therapy alone [10]. For patients unable to
tolerate CPAP (for instance some patients find the facial attachment distressing), standard
oxygen therapy may have to be used as the ceiling-of-care for respiratory support.
The mode of respiratory support used for patients with persistent hypoxemia despite stan-
dard oxygen therapy therefore involves a complex inter-play of disease severity, pre-morbid
status, ceiling-of-care decisions, current local guidelines and local resources [9,10]. The aim of
our study was to evaluate the outcomes of adult patients admitted to two hospital sites in the
UK, who were treated according to national guidelines [9]. We examined factors associated
with mortality, including mode of respiratory support and ceiling-of-care. We hope to shed
light on the role of CPAP as potential bridge to IMV for patients with no ceilings to their
potential care pathways, and as an escalation of respiratory support for patients with a ceiling-
of-care.
Methods
Study setting, design and participants
The Calderdale and Huddersfield NHS Foundation Trust (CHFT) operates as a single centre,
consisting of two acute hospitals on separate sites with over 800 hospital beds in total, and serv-
ing a population of 460,000 across Kirklees and Calderdale in West Yorkshire, England. Prior
to the SARS-CoV-2 pandemic, there were approximately four high-dependency (HDU) beds
across both hospital sites and ten ICU beds. The latter was increased to 26 ICU beds during
the peak of Covid-19 admissions. We conducted a retrospective cohort analysis using routinely
collected de-identified data of patients with nasal/throat swab positive results for SARs-CoV-2,
admitted during the first six weeks of the Covid-19 epidemic in the region (between 10th
March and 19th April). Outcome status (death, discharged alive or still an in-patient) was
determined on 22nd May 2020.
Patient and public involvement
Effective management of Covid-19 is a global priority. Patient and public were not involved in
the design of the study as it involved a retrospective analysis of routinely collected data from
the Electronic Patient Record (EPR). This data was fully anonymised and de-identified prior
to being accessed for inclusion in the analysis and the study.
Procedures
Electronic clinical records were examined, and data collection was adapted from the Interna-
tional Severe Acute Respiratory and Emerging Infection Consortium and WHO standardised
case record proformas. Data was collated by the medical team within the respiratory depart-
ment. In addition, we collected information on care home residency and ceiling-of-care
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planning. We examined all adult patient data with SARs-CoV-2 swab positive results. Clinical
management was according to the NHS Specialty specific guidelines [9]. These state that
“CPAP is the primary mode of non-invasive respiratory support for hypoxic COVID19
patients. Suggested initial settings are 10 cmH2O + 60% oxygen”.
In this study, patients not maintaining oxygen saturations over 92–94% on 40–60% oxygen
via a Venturi mask were commenced on CPAP 10 cm H20 and 10 litres oxygen, adjusted
according to physician discretion. CPAP on the ward was delivered by the Breas Medical
NIPPY 3+© ventilator, with oxygen entrained from the wall via piped oxygen attached to a
flow meter. Pressure could be adjusted as required, to a maximum of 15 cm H2O and flow
could be adjusted to a maximum of 15 litres O2. The default interface used on the ward was a
full face mask, but a total face mask was used in a small number of patients who could not tol-
erate this.
With only one exception, CPAP as a ceiling of care was started on the respiratory wards.
CPAP as a bridge to IMV was started on the respiratory wards in most cases. These wards con-
sisted of three bays of four beds, and four side-rooms consisting of one bed. All beds had access
to a wall-mounted oxygen supply and could support the use of CPAP. One nurse would typi-
cally look after four to eight patients.
Oxygen requirements, which were administered as the minimum required to maintain
target oxygen saturations within the range set by national guidelines, were documented as a
proxy marker for hypoxemia and hence for severity of disease.
Fourteen patients requiring CPAP were commenced on CPAP Hoods instead of face masks
and this was always delivered on ITU, either via the Hamilton-S1©, or the Hamilton-C3© Ven-
tilator. With one exception, all of the CPAP Hood patients remained for full escalation.
Exposure and outcome variables and analysis
The primary outcome was mortality and the main exposure of interest was the maximal respi-
ratory support received, defined as ‘air/oxygen’ for patients who were not escalated to either
CPAP or IMV; ‘CPAP’ for patients who were not escalated to IMV; ‘IMV’ for patients who
were intubated and ventilated (including prior air/oxygen and/or CPAP). A secondary expo-
sure of interest was presence of an early ceiling-of-care plan (defined as pre-existing plans in
place prior to admission or within 24h of admission) (S1 Fig).
The following baseline exposure variables determined by history and clinical assessment by
clinicians, were assessed as potential confounding factors for death: sex, age category, ethnic-
ity, body mass index (BMI), care home residency, pre-existing co-morbidities and clinical fea-
tures at admission. Age was categorized as younger than 70y, 70-79y, 80-89y and�90y to
ensure adequate outcome events in each category.
Continuous variables are presented as medians and inter-quartile ranges (IQRs) and cate-
gorical variables as counts and percentages. Missing values were excluded. Logistic regression
was performed to estimate odds ratios (ORs). Likelihood ratio testing (LRT) was done to assess
statistical evidence of association. The multivariable model included sex as a confounding fac-
tor a priori. Variables which showed evidence of association (p<0.05) with both mortality and
with respiratory support were examined for inclusion in the final multivariable model using a
backward stepwise approach. The final multivariable model included age category, sex, respi-
ratory rate at admission, ceiling-of-care plans (pre-admission/within 24h) and maximal respi-
ratory support received. Patients who had a ceiling-of-care instituted more than 24h after
admission were omitted as reverse causality was possible, i.e. that a ceiling-of-care was intro-
duced following failure to respond to treatment.
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All analyses were performed using Stata™ version 16.0 for Windows (Stata-Corp, College
Station, Texas). Data analysed was departmental, routinely collected and fully anonymized.
The Calderdale and Huddersfield NHS Foundation Trust Research and Development office
considered this project a service evaluation to establish a standard, and did not require further
approval. The database is available on request to the corresponding author.
Results
Patient characteristics in study population overall
During the first six weeks of the Covid-19 epidemic in the Calderdale and Kirklees region of
West Yorkshire (between 10th March and 19th April), 347 adult patients (�18y) had SARs-
CoV-2 positive nasal/throat swabs (S2 Fig). We excluded patients who were not admitted
(N = 18) or were admitted for reasons other than Covid-19, namely those who were swabbed
prior to discharge or during hospitalization following admission for another unrelated reason
(N = 35). Two-hundred and ninety-four (84.7%) patients were included in the final analysis
and 215 (73.1%) of them maximally received air/standard oxygen therapy, 45 (15.3%) received
CPAP and 34 (11.6%) received IMV. Twenty-four of the IMV patients had previously failed
on CPAP and required further escalation.
Ages ranged from 23-102y (median age 71y (IQR 59,82)) (Table 1). One-hundred and
eighty-three (62.2%) patients were male. The majority of patients were White (N = 239,
81.3%), 55 (18.7%) were Asian, 7 (2.3%) Black and 11 (3.7%) patients classified as Other eth-
nicity. Over one-fifth of patients were care home residents (N = 65, 22.1%).
The most common pre-existing co-morbidities were hypertension (N = 109, 37.1%) and
chronic cardiac disease (N = 90, 30.6%) (Table 1). Fifty-six (19.0%) patients had dementia. The
most commonly self-reported symptoms were fever (N = 190, 64.6%), cough (N = 211, 71.8%)
and shortness of breath (N = 181 61.6%) and the median duration since onset of symptoms
was 7 days (IQR 3,10). Temperature measured at admission ranged from 27.8–41.4 degrees
Celsius (median 36.8, IQR 36.4, 37.5) and 52 (17.7%) had a fever (>37.8 degrees Celsius). One
97y old lady was found on the floor at home and was hypothermic (27.8 degrees Celsius).
Respiratory rate at admission ranged from 14–64 breaths/minute (median 23, IQR 20,28) and
heart rates ranged from 21–173 beats/minute (median 92, IQR 78,106). The majority of chest
radiographs revealed bilateral opacities in 204 (69.4%) and 37 (12.5%) patients had unilateral
opacities.
One hundred and fifty-seven of all patients (53.4%) had a ceiling-of-care plan of which 138
(87.9%) were instituted early (63 pre-admission and 75 within 24h of admission). The remain-
ing 19 patients with a ceiling-of-care had it instituted later during admission. The median age
of early ceiling-of-care patients (N = 138) was 81y (IQR 74,87) compared to median age of 59y
(IQR 52,68) among patients with no ceiling-of-care (N = 137). Among early ceiling-of-care
patients, standard oxygen therapy was the ceiling of respiratory support planned for 84
(60.9%) patients, CPAP for 41 (29.7%) patients and it was not pre-specified for 13 patients
(9.4%) (the latter all went on to maximally receive air/oxygen). Ninety-five percent (N = 62) of
care home residents had a ceiling-of-care, with the majority (64.5% (N = 40)) already having a
ceiling plan before admission.
Characteristics of patients by maximal respiratory support received
We examined patient characteristics separately by maximal respiratory support received
(Table 2). Age and sex were strongly associated with maximal respiratory support received.
Two care home residents received CPAP, but all remaining 63 maximally received air/oxygen
therapy. There was statistical evidence of association (X2 test) with maximal respiratory
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Table 1. Patient characteristics overall.
Patients overall N (%)
Socio-demographic characteristics
Sex Female 111 (37.8)
Male 183 (62.2)






� 90 21 (7.1)
Ethnicity White 239 (81.3)
Asian 55 (12.6)
Black & other1 18 (6.1)




� 30 76 (35.9)
Care home resident 65 (22.1)
Pre-existing comorbidities2
Hypertension 109 (37.1)
Chronic cardiac disease 90 (30.6)
Diabetes mellitus without complications 56 (19.1)
Diabetes mellitus with complications 26 (8.9)
Dementia 56 (19.1)
Chronic pulmonary disease 49 (16.7)
Chronic neurological disorder 38 (12.9)
Asthma 34 (11.6)
Chronic kidney disease 28 (9.5)
Rheumatological condition 22 (7.5)
Malignant neoplasm 20 (6.8)
Clinical features at admission3
Days since onset of symptoms (N = 253) Median (IQR) 7 (3,10)
Fever 190 (67.1)
Cough 211 (73.5)
Shortness of breath 181 (62.9)
Temperature (degrees Celsius) Median (IQR) 36.8 (36.4,37.5)
Respiratory rate (breaths per minute) Median (IQR) 23 (20,28)
Heart rate (beats per minute) Median (IQR) 92 (78,106)
CXR at admission Clear4 53 (18.0)
Unilateral opacities 37 (12.6)
Bilateral opacities 204 (69.4)
Management
Ceiling-of-care None 137 (46.6)
Pre-admission 63 (40.1)
Within 24 hours 75 (47.8)
Later during admission 19 (12.1)
(Continued)
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support received and the following pre-morbidities chronic cardiac disease (p = 0.008),
dementia (p<0.001) and chronic neurological disease (p = 0.03) indicating a greater preva-
lence in patients maximally treated with air or oxygen, than patients treated with CPAP or
IMV. Having diabetes mellitus with complications was also different depending on maximal
respiratory support (p = 0.009), with the higher prevalence among CPAP patients, while
asthma (p = 0.02) was more common among IMV patients.
Duration since onset of symptoms was strongly associated with maximal respiratory sup-
port received (p<0.001). Air/oxygen patients had a shorter median duration of symptoms of 5
days compared with CPAP and IMV patients (both 7 days). There was statistical evidence
across clinical characteristics to indicate that patients maximally requiring CPAP or IMV had
more severe disease than air/oxygen patients, based on reported symptoms, vital signs and
chest radiography.
Among all air/oxygen patients, 28.8% (N = 62) had a ceiling-of-care plan in place prior to
admission and a further 26.5% (N = 57) had a plan developed in the first 24h of admission.
Nineteen patients (42.2%) maximally received CPAP and had an early ceiling-of-care, and all
but one were planned during the first 24h of admission. Overall, ninety-two patients received
maximal respiratory support with air/oxygen as planned, while among 76 patients who had a
ceiling-of-care plan which allowed for escalation to CPAP, 51 (67.1%) received air/oxygen
only. Fourteen patients with ceilings-of-care did not have mode of planned maximal respira-
tory support recorded.
Patient outcomes
Overall 103 (35.0%) patients died and 187 (63.6%) recovered and were discharged. Four
patients (1.4%) remained in hospital at the end of the observation period (median duration–
38 days (IQR 35,40)). The overall number of days of hospitalization ranged from 0 to 42 days
(ten patients were discharged and one patient died on the same day of admission), with a
median of 7 days (IQR 3,11). The mortality among patients maximally requiring and receiving
air/oxygen was 33.0% (N = 71); CPAP was 46.7% (N = 21); IMV was 41.2% (N = 14) (Fig 1).
There was no evidence to suggest a difference in median duration of hospitalization between
air/oxygen and CPAP patients (6 days (IQR 3,10) and 7 days (IQR 5,11), respectively (X2
p = 0.11)) but there was strong evidence for a difference between each of these groups and
IMV (24 days (IQR 7,36) (X2 p<0.001)).
Mortality by respiratory support received and ceiling-of-care
Patients who were hypoxemic despite standard oxygen therapy, and who required escalation
to CPAP, had the highest mortality overall, especially in the sub-group with a ceiling-of-care
Table 1. (Continued)
Patients overall N (%)
Maximal respiratory support Air/oxygen 215 (73.1)
CPAP 45 (15.3)
IMV 34 (11.6)
1 Black N = 7 & Other N = 11;
2 Co-morbidities with at least 5% prevalence in study population;
3 Three mostly commonly reported symptoms are shown;
4 Thirteen patients had non-Covid related changes.
https://doi.org/10.1371/journal.pone.0244857.t001
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Table 2. Patient characteristics by maximal respiratory support received.
Air/oxygen1 215 (%) CPAP2 45 (%) IMV3 34 (%) X2 test p-value4
Socio-demographic characteristics
Age (y) Median (IQR) 76 (63,85) 67 (56,73) 59 (51,67) <0.001
20–49 19 (8.9) 5 (11.1) 8 (23.5) <0.001
50–59 26 (12.1) 10 (22.2) 10 (29.4)
60–69 32 (14.9) 11 (24.4) 11 (32.4)
70–79 54 (25.1) 16 (35.6) 5 (14.7)
80–89 64 (29.8) 2 (4.4) 0 (0.0)
� 90 20 (9.3) 1 (2.2) 0 (0)
Sex Female 94 (43.7) 9 (20) 8 (23.5) 0.002
Male 121 (56.3) 36 (80) 26 (76.5)
Ethnicity White 179 (83.3) 35 (77.8) 25 (73.5) 0.36
Asian 22 (10.2) 8 (17.8) 7 (20.6)
Black, Other 14 (6.5) 2 (4.4) 2 (5.9)
BMI Median (IQR) 26.4 (22.3,31.1) 29.8 (24.6,33.5) 29.2 (26.8,32.9) 0.02
15–19.9 13 (8.4) 1 (3.7) 0 (0.0) 0.14
20–24.9 51 (32.9) 7 (25.93) 5 (16.7)
25–29.9 41 (26.5) 6 (22.2) 12 (40.0)
� 30 50 (32.3) 13 (48.2) 13 (43.3)
Missing 60 (27.9) 18 (40.0) 4 (11.8)
Care home resident 63 (29.3) 2 (4.4) 0 (0.0) <0.001
Pre-existing comorbidities
Hypertension 77 (35.8) 20 (44.4) 12 (35.3) 0.54
Chronic cardiac disease 75 (34.9) 12 (26.7) 3 (8.8) 0.008
Diabetes mellitus without complications 42 (19.5) 8 (17.8) 6 (17.7) 0.94
Diabetes mellitus with complications 13 (6.1) 9 (20.0) 4 (12.1) 0.009
Dementia 54 (25.1) 2 (4.4) 0 (0) <0.001
Chronic pulmonary disease 36 (16.7) 9 (20.0) 4 (11.8) 0.62
Chronic neurological disease 35 (16.3) 2 (4.4) 1 (2.9) 0.02
Asthma 24 (11.2) 2 (4.4) 8 (23.5) 0.03
Chronic kidney disease 23 (10.7) 4 (8.9) 1 (2.9) 0.35
Rheumatological condition 19 (8.8) 3 (6.7) 0 (0) 0.19
Malignant neoplasm 17 (7.9) 3 (6.8) 0 (0) 0.24
Clinical features at admission
Days since onset of symptoms Median (IQR) 5 (2,9) 7 (4,12) 7 (6,10) <0.001
Missing 38 (17.7) 2 (4.4) 1 (2.9)
Fever 32 (61.4) 30 (66.7) 28 (82.6) 0.03
Missing 9 (4.2) 0 (0) 2 (5.9)
Cough 141 (65.6) 39 (86.7) 31 (91.2) 0.002
Missing 7 (3.3) 0 (0) 0 (0)
Shortness of breath 123 (57.2) 33 (73.3) 25 (73.5) 0.05
Missing 5 (2.3) 0 (0) 1 (2.9)
Temperature Median (IQR) 36.7 (36.3,37.3) 37.2 (36.7,37.7) 37.4 (36.5,38.2) <0.001
Respiratory rate Median (IQR) 22 (19, 26) 26 (20, 29) 28 (24, 32) <0.001
Heart rate Median (IQR) 90 (74, 106) 97 (78, 108) 98 (86, 110) 0.04
CXR at admission Clear5 51 (23.7) 2 (4.4) 0 (0.0) <0.001
Unilateral opacities 35 (16.3) 1 (2.2) 1 (2.9)
Bilateral opacities 129 (60.0) 42 (93.3) 33 (97.1)
(Continued)
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(Fig 1). However, when patients without a ceiling-of-care are examined separately, mortality is
highest among IMV patients (41.2% N = 14), and only one patient in each of the air/oxygen
(1.2%) and CPAP (5.0%) sub-groups died.
When all patients who ever received CPAP (including those who went on to require IMV
N = 69) are examined, 19 patients had an early ceiling-of-care plan, and 84.2% of these patients
died. Among those without any ceiling-of-care (N = 44), 75% recovered and were discharged–
43.1% (N = 19) without requiring IMV and 31.8% (N = 14) after subsequently receiving IMV
(Fig 2).
Factors associated with mortality
Older age is strongly associated with a higher risk of death from Covid-19 (Table 3). Sex, BMI
and residence in a care home were crudely associated with mortality but after adjusting for age
there was no statistical evidence of association. This was also the case for a number of pre-
Table 2. (Continued)
Air/oxygen1 215 (%) CPAP2 45 (%) IMV3 34 (%) X2 test p-value4
Ceiling of care timing Never 83 (38.6) 20 (44.4) 34 (100)
Pre-admission 62 (28.8) 1 (2.2) -
Within 24 hours 57 (26.5) 18 (40.0) -
Later during admission 13 (6.1) 6 (13.3) -
1Air only (N = 55), oxygen via nasal prongs (N = 72), via face mask (N = 54), via non-rebreather mask (N = 34);
2 Seven patients had CPAP with helmet and 38 had CPAP with face mask;
3 Ten patients escalated directly to IMV from air/oxygen while 24 were trialled on CPAP before IMV;
4Kruskal-Wallis equality-of-populations rank test was used to compare median values.
https://doi.org/10.1371/journal.pone.0244857.t002
Fig 1. Mortality of patients by maximal respiratory support received, overall and stratified by ceiling-of-care.
https://doi.org/10.1371/journal.pone.0244857.g001
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morbidities, namely hypertension, chronic cardiac disease and dementia. Having an early ceil-
ing-of-care pre-admission/within 24 hours of admission was associated with over 40 times the
odds of death in the multivariable analysis (aOR 41.81 95% CI 8.28, 211.17; p<0.001), com-
pared to patients with no ceiling-of-care. Maximal respiratory support with CPAP and IMV
was not associated with higher mortality compared to air/oxygen in the crude analysis (OR
1.77 95% CI 0.93, 3.40 and OR 1.42 (0.68, 2.97), respectively; p = 0.19). After adjusting for con-
founding factors there was strong evidence for higher mortality among hypoxemic patients
who required escalation to CPAP or IMV (aOR 5.24 95% CI 1.38, 19.81 and aOR 46.47 95% CI
7.52, 287.08, respectively; p<0.001) compared to air/oxygen, although the confidence intervals
were overlapping and were wide especially for IMV, due to the small sample.
Discussion
In our cohort of 294 hospitalised patients, 69 were trialled on CPAP either as a ceiling-of-care
(N = 25), of which only those with an early ceiling-of-care (N = 19) were included in the analy-
sis, or as a potential bridge to IMV (N = 44). Among patients who were trialled on CPAP as a
potential bridge to IMV 75% survived—43.2% (N = 19) survived without requiring IMV and a
further 31.8% (N = 14) after IMV (Fig 2). Patients who maximally received CPAP also spent
significantly less time in hospital compared to IMV patients (median 7 days vs 24 days, X2
p<0.001). The implications of our findings are that a trial of CPAP prior to intubation appears
to be an effective treatment strategy in selected patients and may have significant benefits
both for patient well-being and health system resources, especially in settings where IMV
and accompanying intensive care beds are scarce.
In contrast to patients who had CPAP as a potential bridge to IMV, a high mortality was
observed among patients on CPAP as a ceiling-of-care (Fig 1), reflecting both severity of dis-
ease, as well as frailty, age and co-morbidities in this cohort [11,12].
Overall, in patients with a ceiling of care, mortality was 5 times higher in those requiring
CPAP than in patients treated maximally with air/oxygen after adjusting for confounding fac-
tors, importantly age. This higher relative mortality is to be expected, given that the indication
Fig 2. Outcomes among all patients who ever received CPAP, by ceiling-of-care status (numbered version).
https://doi.org/10.1371/journal.pone.0244857.g002
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Table 3. Characteristics of patients who died and predictors of mortality.
Patients overall Proportion died n/N (%) or median (IQR) Crude odds ratio (OR)1
(95% Confidence Interval
(CI); Likelihood Ratio Test
(LRT) p-value)
Age category adjusted
OR2 (95% CI; LRT p-
value)
Multivariable OR3 (95% CI;
LRT p-value)
Socio-demographic characteristics
Age (y) 20–49 2/30 (6.7) - 0.001 - <0.001
50–59 5/41 (12.2)
60–69 15/54 (27.8)
70–79 32/75 (42.7) 3.72 (1.95,7.11) 3.33 (1.11,9.86)
80–89 35/66 (53.0) 5.65 (2.90,10.99) 4.76 (1.44,15.79)
� 90 17/21 (80.1) 21.25 (6.52,69.26) 15.72 (3.15,78.47)
Sex Female 36/111 (32.4) - 0.31 - 0.04 - 0.13
Male 70/183 (38.3) 1.29 (0.79,1.12) 1.78 (1.02,3.12) 1.70 (0.85,3.41)
Ethnicity White 94/239 (39.3) - 0.02 - 0.71 - 0.77
Asian, Black, Other 12/55 (21.8) 0.43 (0.22,0.86) 0.86 (0.39,1.90) 0.85 (0.29,2.53)
BMI4 26 (22.4,30) 0.95 (0.90,0.99) 0.03 0.98 (0.94,1.04) 0.56 1.00 (0.94,1.07) 0.87
Care home resident 37/65 (56.9) 3.06 (1.74,5.40) <0.001 1.63 (0.86,3.07) 0.13 1.51 (0.69,3.33) 0.30
Pre-existing comorbidities
Hypertension 47/109 (43.1) 1.62 (0.99,2.64) 0.05 1.29 (0.75,2.21) 0.36 1.16 (0.58,2.32) 0.67
Chronic cardiac disease 48/90 (53.3) 2.88 (1.72, 4.81) <0.001 1.43 (0.79,2.59) 0.23 1.18 (0.57,2.43) 0.66
Diabetes mellitus without
complications
23/56 (41.1) 1.30 (0.72, 2.36) 0.39 1.30 (0.67,2.49) 0.44 1.15 (0.51,2.66) 0.73
Diabetes mellitus with
complications
13/26 (50.0) 1.89 (0.84, 4.25) 0.12 3.10 (1.27,7.55) 0.01 2.73 (0.87,8.52) 0.09
Dementia 32/56 (57.1) 2.95 (1.63,5.36) <0.001 1.45 (0.74,2.85) 0.28 1.48 (0.68,3.24) 0.32
Chronic pulmonary disease 21/49 (42.9) 1.41 (0.76,2.63) 0.28 1.13 (0.57,2.23) 0.73 0.91 (0.41,2.04) 0.82
Chronic neurological disorder 17/38 (44.78) 1.52 (0.76,3.03) 0.24 1.39 (0.65,2.95) 0.39 1.15 (0.45,2.96) 0.76
Asthma 9/34 (26.5) 0.61 (0.27,1.35) 0.22 0.77 (0.33,1.82) 0.56 0.85 (0.30,2.42) 0.76
Chronic kidney disease 13/28 (46.4) 1.61 (0.74,3.53) 0.23 0.94 (0.40,2.23) 0.89 1.20 (0.43,3.33) 0.73
Rheumatological condition 6/22 (27.3) 0.65 (0.24,1.70) 0.38 0.46 (0.16,1.31) 0.15 0.57 (0.17,1.94) 0.37
Malignant neoplasm 7/20 (35.0) 0.96 (0.37,2.49) 0.94 0.64 (0.23,1.76) 0.39 0.64 (0.18,2.19) 0.47
Clinical features at admission
Temperature (degrees
Celsius)
36.7 (36.3,37.5) 0.82 (0.65,1.03) 0.09 1.00 (0.77,1.29) 0.99 0.84 (0.58,1.23) 0.38
Respiratory rate (breaths per
minute)
24 (21,30) 1.08 (1.04,1.12) <0.001 1.12 (1.07,1.18) <0.001 1.09 (1.03,1.15) 0.003




80/138 (58.0) 10.43 (5.60,19.42) <0.001 6.91 (3.09,15.46) <0.001 41.81 (8.28,211.17) <0.001
Maximal respiratory support
Air/oxygen 68/215 (31.6) - 0.19 - <0.001 <0.001
CPAP 21/45 (46.7) 1.77 (0.93,3.40) 5.41 (2.32,12.64) 5.24 (1.38,19.81)
IMV 14/34 (41.2) 1.42 (0.68, 2.97) 7.86 (2.93,21.08) 46.47 (7.52, 287.08)
1 Logistic regression models were generated whereby for continuous variables the ORs are for each unit increase in value of the given characteristic; for binary variables
the reference category was the absence of a given characteristic; for other categorical variables the reference category is indicated in the table; where there were low
number of deaths, categories are combined as shown for age and ethnicity;
2 Adjusted for age category as in 4 categories: 20-69y, 70-79y, 80-89y,�90y;
3 Adjusted for age category, sex, ceiling-of-care pre-admission or within 24h, diabetes mellitus with complications (ie end organ damage) and maximal respiratory
support received;
4 Missing values for BMI (N = 82) were excluded;
5 Patients who had a ceiling-of-care introduced after failure to respond to treatment were excluded (N = 19).
https://doi.org/10.1371/journal.pone.0244857.t003
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for CPAP in these patients is hypoxemia not controlled on standard oxygen therapy, due to
more severe Covid-19. Mortality among patients with a ceiling-of-care was over 40 times
higher than among those without any limits to their potential treatment pathways even after
adjusting for age and other confounding factors, likely reflecting treatment limitations, pre-
existing frailty and the burden of other co-morbidities in these patients, which we were not
able to adjust for.
Existing evidence for CPAP in severe acute respiratory distress is conflicting, and much of
it was initially based on non-Covid-19 pathology [13]. A study examining CPAP use in SARS
found that CPAP avoided IMV in 70% of patients [14]. Conversely, a study of non-invasive
ventilation in critically ill patients with MERS found that over 90% of patients initially treated
with non-invasive ventilation required intubation [15]. Studies from Wuhan, China demon-
strated a mortality after CPAP of 44–72% with Covid-19 [16,17]. The extent to which the high
mortality related to pre-morbid frailty, treatment limitations, severity of disease or a combina-
tion is unclear. UK guidelines recommend that when ICU capacity is limited, CPAP (as the
preferred form of non-invasive ventilatory support) should be trialed in COVID-19 patients
who remain hypoxemic despite standard oxygen therapy [18]. Data from the ISARIC/WHO
CCP-UK study on>20,000 Covid-19 patients from 208 acute hospitals across the country
indicate that 16% of patients were trialed on CPAP during admission for Covid-19, which is
similar to our study [2]. In contrast, data from the US suggest that as little as 1–2% of patients
admitted to ICU had a trial of CPAP prior to intubation [3,19].
Alternative modes of non-invasive respiratory support may be superior to CPAP delivered
by face mask [20]. In our study, only 14 patients had CPAP with a helmet. A previous rando-
mised trial has demonstrated superiority of CPAP with helmets over CPAP via face masks in
avoiding endotracheal intubation (62% vs. 18%) in non-Covid pathology [21]. High-flow oxy-
gen through nasal cannula in acute hypoxemic respiratory failure has also been shown to be
effective, but the high oxygen consumption associated with this method may present a serious
challenge with any surge in demand, hence this was not widely used in the UK [22]. The
increased infectious risk posed to healthcare workers from administering non-invasive ventila-
tion modalities such as CPAP also requires further research [14,23]. Randomized controlled
trials are underway to identify the most effective form of non-invasive pressure support in
Covid-19 in reducing the need for intubation [24,25]. Studies are also emerging globally con-
firming the usefulness of ward-based CPAP for Covid patients [26,27]. In the meantime, our
study provides important insights into the potential utility and limitations of CPAP.
The sample size in this study was relatively small. However, characteristics of our study
population were similar to the ISARIC/WHO CCP-UK study data across key features includ-
ing sex, age, prevalence of co-morbidities and mortality, suggesting that our patients are
representative of UK Covid-19 patients [2]. We have not accounted for other treatments our
patients received, including as part of the RECOVERY trial which most patients were enrolled
in [28]. However, as the trial randomised treatment allocation it is unlikely it would have sys-
tematically biased our findings. We have been able to provide novel data on ceilings-of-care
and its impact on outcomes from Covid-19. We also had final outcomes on almost all our
patients with just 4 still hospitalised in contrast to many other clinical cohorts on Covid-19
[3,17,19,29].
Our data indicate care home residents are not more likely to die after accounting for age in
our study. This is re-assuring with regard to the clinical treatment received in hospital by this
sub-group of patients against the background of the concerning public health data on the high
death toll from Covid-19 among care home residents [30]. Almost a fifth of our patients were
of Asian ethnicity, but these patients were on average younger than the majority white popula-
tion, and it was not associated with increased mortality in our study.
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The global scale of the pandemic has the potential to overwhelm many health systems, espe-
cially ICU resources. There is an urgent imperative for health systems faced with the prospect
of shortage of ventilators to harness the role of ventilator-sparing strategies in the treatment of
Covid-19 [31–33]. Our data suggest that among patients with no ceiling-of-care, an initial trial of
CPAP in selected patients seems a reasonable therapeutic strategy and may potentially delay or
even avert the need for intubation in some patients. In contrast, our findings indicate that the use
of CPAP among patients with a ceiling-of care has a high failure rate, and it should be used judi-
ciously in close consultation with patients and their representatives where feasible. Further
research on this matter would help future management. Our data highlights the importance of
accounting for ceilings of respiratory support when interpreting mortality from Covid-19.
This study has provided novel evidence on the respiratory support of patients with Covid-
19 and could have significant implications for patients and health systems faced with the
unprecedented impact of the pandemic.
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